Grand Pharmaceutical Group Limited (HKG:0512)
Hong Kong · Delayed Price · Currency is HKD 4.735
-0.100 (-2.07%)
Sep 11, 2026, 4:08 PM HKT
HKG:0512 Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 12,483 | 12,283 | 11,645 | 10,530 | 9,562 | 8,598 | |
Revenue Growth | 6.65% | 5.48% | 10.59% | 10.12% | 11.22% | 35.34% |
Cost of Revenue | 5,988 | 5,503 | 4,907 | 4,006 | 3,611 | 3,351 |
Gross Profit | 6,495 | 6,780 | 6,738 | 6,524 | 5,951 | 5,247 |
Selling, General & Admin | 4,821 | 5,195 | 4,621 | 3,802 | 3,396 | 3,307 |
Other Operating Expenses | -61.03 | -221.52 | -176.83 | -195.17 | -170.42 | -242.12 |
Operating Expenses | 4,799 | 5,013 | 4,517 | 3,665 | 3,203 | 3,077 |
Operating Income | 1,696 | 1,767 | 2,221 | 2,860 | 2,748 | 2,170 |
Interest Expense | -157.1 | -162.34 | -180.24 | -205.15 | -137.49 | -92.96 |
Interest & Investment Income | 7.37 | 7.37 | 6.31 | 7.75 | 19.81 | 74.95 |
Earnings From Equity Investments | 76.43 | 76.06 | 148.72 | -25.01 | -43.79 | 113.86 |
Other Non Operating Income (Expenses) | 0.9 | 0.9 | -27.78 | -32.34 | 40.1 | -8.35 |
EBT Excluding Unusual Items | 1,623 | 1,689 | 2,168 | 2,605 | 2,627 | 2,258 |
Merger & Restructuring Charges | -0.62 | -0.62 | -1.3 | - | -0.22 | - |
Impairment of Goodwill | - | - | -49.07 | -39.14 | -36.44 | - |
Gain (Loss) on Sale of Investments | -249.53 | -189.31 | 675.93 | 89.27 | -94.62 | 484.85 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 2.37 |
Asset Writedown | -4.87 | -4.87 | 4.39 | 5.45 | 21.35 | 29.58 |
Other Unusual Items | - | - | 54.21 | -316.18 | - | 11.42 |
Pretax Income | 1,368 | 1,494 | 2,852 | 2,344 | 2,517 | 2,786 |
Income Tax Expense | 258.48 | 249.78 | 386.3 | 448.76 | 418.64 | 380.8 |
Earnings From Continuing Operations | 1,110 | 1,244 | 2,466 | 1,895 | 2,098 | 2,405 |
Minority Interest in Earnings | -0.37 | -3.43 | 2.32 | -15.44 | -18.83 | -2.47 |
Net Income | 1,109 | 1,241 | 2,468 | 1,880 | 2,079 | 2,403 |
Net Income to Common | 1,109 | 1,241 | 2,468 | 1,880 | 2,079 | 2,403 |
Net Income Growth | -46.66% | -49.73% | 31.30% | -9.59% | -13.45% | 34.02% |
Shares Outstanding (Basic) | 3,502 | 3,502 | 3,502 | 3,508 | 3,542 | 3,548 |
Shares Outstanding (Diluted) | 3,502 | 3,502 | 3,502 | 3,508 | 3,542 | 3,548 |
Shares Change | 0.08% | - | -0.17% | -0.97% | -0.16% | 2.98% |
EPS (Basic) | 0.32 | 0.35 | 0.70 | 0.54 | 0.59 | 0.68 |
EPS (Diluted) | 0.32 | 0.35 | 0.70 | 0.54 | 0.59 | 0.68 |
EPS Growth | -46.70% | -49.73% | 31.52% | -8.70% | -13.31% | 30.14% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | 923.37 | 1,342 | 1,937 | 1,216 | 1,534 |
Free Cash Flow Per Share | - | 0.26 | 0.38 | 0.55 | 0.34 | 0.43 |
Dividend Per Share | - | 0.169 | 0.260 | 0.260 | 0.140 | 0.110 |
Dividend Growth | - | -35.00% | 0% | 85.71% | 27.27% | 0% |
Gross Margin | 52.03% | 55.20% | 57.87% | 61.96% | 62.24% | 61.03% |
Operating Margin | 13.58% | 14.38% | 19.07% | 27.16% | 28.74% | 25.24% |
Profit Margin | 8.89% | 10.10% | 21.20% | 17.85% | 21.75% | 27.94% |
Free Cash Flow Margin | - | 7.52% | 11.53% | 18.40% | 12.72% | 17.84% |
EBITDA | 2,249 | 2,310 | 2,675 | 3,212 | 3,109 | 2,493 |
EBITDA Margin | 18.02% | 18.80% | 22.97% | 30.50% | 32.52% | 28.99% |
D&A For EBITDA | 553.62 | 542.84 | 453.38 | 352.36 | 361.05 | 322.53 |
EBIT | 1,696 | 1,767 | 2,221 | 2,860 | 2,748 | 2,170 |
EBIT Margin | 13.58% | 14.38% | 19.07% | 27.16% | 28.74% | 25.24% |
Effective Tax Rate | 18.89% | 16.72% | 13.54% | 19.14% | 16.63% | 13.67% |